Currently, prescribing pharmacists in the UK cannot prescribe cannabis-based products for medicinal use (CBPMs). Prescribing of CBPMs for medicinal use in the UK is restricted to only those clinicians listed on the Specialist Register of the General Medical Council¹. The GMC² does not specify what type of speciality is needed (there are over 60 possible […]
In the latter half of 2020, it has been reported in the popular press¹’²’³, that a number of school-aged children from Camden, London, UK have been taken to hospital having taken imitation “Nerds” sweets containing the psychoactive element of cannabis, THC. The pack (see above) states it contains a total amount of 600 mg of […]
Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide. On March 5, 2019, the nasal spray drug, esketamine, also known as Spravato (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression. Depression is a common and debilitating condition that is recognised as a leading cause of […]
Spravato is the brand name of esketamine, a glutamate receptor drug used for rapid depression treatment manufactured by Johnson & Johnson in the US. Esketamine contained within the standard pharmaceutical form of ketamine, which has traditionally been used at higher doses as an anaesthetic. The difference between Esketamine and Ketamine is that the latter contains the […]
Spravato is the brand name of esketamine, a nasally adminitsered medicine used for the rapid treatment of moderate to severe depression. Spravato was initially released by Johnson & Johnson in the US at the beginning March 2019. In the UK, it is now a medcine (by Janssen-Cilag) and available from specialist psychiatric prescribers and pharmacies […]